Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

被引：0
|
作者：
Yang, Yunpeng
Zhao, Yuanyuan
Fang, Wenfeng
Huang, Yan
Zhang, Yaxiong
Ba, Yi
Wang, Zhen
Deng, Chao
Hu, Desheng
Wang, Wei
Li, Guiling
Luo, Suxia
Fu, Zhichao
Zhu, Haisheng
Wang, Huili
Zhao, Shiwei
Li, Tao
Cai, Charles
Zhang, Li
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT227
引用
收藏
页数：2
相关论文
共 50 条
  • [41] First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
    Piha-Paul, Sarina A.
    Geva, Ravit
    Tan, Tira J.
    Lim, Darren Wt
    Hierro, Cinta
    Doi, Toshikiko
    Rahma, Osama
    Lesokhin, Alexander
    Luke, Jason John
    Otero, Javier
    Nardi, Lisa
    Singh, Angad
    Xyrafas, Alexandros
    Chen, Xinhui
    Mataraza, Jennifer
    Bedard, Philippe L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [42] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
    Bendell, Johanna
    Ulahannan, Susanna V.
    Chu, Quincy
    Patel, Manish
    George, Ben
    Landsberg, Renee
    Elgadi, Mabrouk
    Duffy, Christine
    Graeser, Ralph
    Tang, Wenbo
    Merger, Michael
    Ge, Miaomiao
    Johnson, Melissa
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [44] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis
    Mehmi, Inderjit
    Lewis, Karl D.
    Weise, Amy M.
    McKean, Meredith
    Papadopoulos, Kyriakos P.
    Crown, John
    Thomas, Sajeve Samuel
    Girda, Eugenia
    Kaczmar, John M.
    Kim, Kevin B.
    Lakhani, Nehal J.
    Yushak, Melinda Lynne
    Hamid, Omid
    Mani, Jayakumar
    Fang, Fang
    Lowy, Israel
    Gullo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study (POLARIS-03)
    Sheng, Xinan
    Chen, Haige
    Hu, Bin
    Yao, Xudong
    Liu, Ziling
    Yao, Xin
    Guo, Hongqian
    Hu, Yi
    Ji, Zhigang
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    Wu, Jin
    Zhou, Fang-Jian
    He, Zhisong
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [47] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [49] Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.
    Moore, Kathleen N.
    Dresher, Charles
    Liu, Joyce
    O'Malley, David M.
    Wang, Edward Wenge
    Wang, Judy Sing-Zan
    Subbiah, Vivek
    Wilky, Breelyn A.
    Yuan, Guojun
    Dupont, Christopher D.
    Gonzalez, Ana M.
    Savitsky, David
    Coulter, Sara
    Shebanova, Olga
    Dow, Ed
    Proscurshim, Igor
    Buell, Jennifer
    Stein, Robert Benjamin
    Youssoufian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
    Gong, Jifang
    Guo, Ye
    Zhang, Yanqiao
    Ba, Yi
    Chen, Tong
    Li, Wei
    Zhou, Caicun
    Wang, Mengzhao
    Yang, Haiyan
    Zhou, Yuhong
    Cai, Qiqing
    Wang, Ziping
    Huang, Gang
    Zhang, Wei
    Su, Rila
    Cai, Zhongheng
    Yue, Zenglian
    Dou, Jinzhou
    Li, Peiqi
    Wu, Rachel
    Tse, Archie N.
    Shen, Lin
    TARGETED ONCOLOGY, 2024, 19 (05) : 723 - 733
12345